AUTHORS
Xia Chen, Fang Liu2, Xiaofan Zhu, MD3, Wenyu Yang4
AFFILIATIONS
1 Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China, Tianjin, China
2 Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China, Tianjin, China
3 Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China, Tianjin, China
4 Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China, Tianjin, China
ABSTRACT
Background: The relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT) represents the most critical risk factor for mortality in patients with malignant hematologic diseases. However, the connection between immune reconstitution and the relapse risk of pediatric patients undergoing allo-HSCT remains unclear. Therefore, the aim of this study was to evaluate the impact of lymphocyte subsets in children diagnosed with malignant hematologic diseases after allo-HSCT.
Methods: We conducted a retrospective analysis of 162 patients who underwent allo-HSCT at our institution. Comprehensive clinical data were collected for all patients, including flow cytometric assessment of lymphocyte subsets on day30 post-transplant.
Results:
1.A retrospective analysis was conducted on 364 patients aged 18 years or younger who underwent HSCT at our center between December 2017 and June 2024. Patients meeting any of the following criteria were excluded: (1) Congenital or Acquired Aplastic Anemia (n = 91). (2) Childhood MDS with low blasts (cMDS-LB) (n=20). (3) Absence of lymphocyte subsets testing at day+30 (n = 76); (4) Primary graft failure (n = 9); (5) Death within 30 days post-transplantation (n = 6). A total of 162 pediatric patients were included in the study, 74 cases of acute myeloid leukemia (AML), 58 cases of acute lymphocytic leukemia (ALL), 10 cases of acute leukemia of ambiguous lineage (ALAL) and 20 cases of MDS with increased blasts (MDS-IB) / Myeloproliferative Neoplasm (MPN).
The median time to onset of relapse was 1119.5 (range:41-3069) days after transplantation. Among the 162 patients, 35 cases relapsed with a rate of 21.6%. The 5-year non-relapse survival is 77.18±3.63%. A comparison of lymphocyte subsets at day30 post-transplant between relapsed and non-relapsed pediatric patients revealed that CD3+T cell counts at 30 days after transplantation were significantly higher in the relapsed patients than in the non-relapsed group (96/ul vs.78/ul, P=0.045), especially CD3+CD4+ T cells (98/ul vs.77/ul, P=0.02). Subgroup analysis revealed that the CD3+T cells (P=0.046) and CD3+CD4+ T cells(P=0.042)were related to ALL patients, whereas no such association was observed in other diseases, including AML, ALAL, MDS-IB, and MPN.
Pre-transplant first complete remission (CR1) status was associated with post-transplant relapse (P=0.02). Subgroup analysis revealed that this correlation remained statistically significant exclusively in ALL patients (P=0.038), whereas no such association was observed in other diseases, including AML, ALAL, MDS-IB, and MPN.
No statistically significant associations with post-transplant relapse were observed for the following variables (all P > 0.05): transplant type (peripheral blood stem cell transplantation vs. unrelated cord blood transplantation), receipt of matched sibling donor or not, BMI, gender matching, ABO blood group compatibility, total infused nucleated cell count, CD34+ cell count, antithymocyte globulin (ATG) usage or not, high-dose ATG exposure (defined as cumulative dose ≥10 mg/kg) or not, cladribine or fludarabine in the conditioning regimen, use of total body irradiation (TBI) or busulfan (BU) in the conditioning regimen, occurrence of grade III–IV acute graft-versus-host disease (aGVHD), and infections including cytomegalovirus (CMV), Epstein-Barr virus (EBV), parvovirus B19, and bacterial sepsis. Additionally, time to neutrophil and platelet engraftment, as well as absolute counts of CD3+CD8+ T cells, CD19+ B cells, and CD3-CD16+CD56+ NK cells at day30 post-transplant, were not significantly associated with relapse risk.
To better clarify the significance of various factors on relapse to ALL patients, we transformed continuous variables into categorical variables using a ROC curve analysis. The cutoff value for CD3+CD4+ T cell count was 74.5/µL (95% CI 0.537 to 0.827, P=0.042). Univariable analysis found that the 5-year incidence of relapse in pediatric ALL patients with CD3+CD4+ T lymphocyte count <74.5/µL was significantly lower than in those with count ≥74.5/µL (7.4% vs 38.7%, P=0.005). The multivariable analysis also found that only the high CD3+CD4+ T cell count was a relapse risk factor (HR 5.052, 95% CI 1.246 to 24.934, P =0.025), pre-transplant CR1 status did not retain independent significance (P = 0.937).
Conclusion: A high CD3+CD4+ T lymphocyte count at day30 post-transplant may serve as a relapse predictor of ALL patients.
DISCLOSURES
Xia Chen: No relevant conflicts of interest to declare.